Drug Type Monoclonal antibody |
Synonyms GC-33, RG 7686, RG-7686 + [2] |
Target |
Mechanism GPC3 inhibitors(Glypican-3 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Antibody-dependent cellular phagocytosis (ADCP) effects |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic hepatocellular carcinoma | Phase 2 | US | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | JP | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | BE | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | FR | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | DE | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | HK | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | IT | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | NZ | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | SG | 02 Feb 2012 | |
Metastatic hepatocellular carcinoma | Phase 2 | KR | 02 Feb 2012 |
Phase 1 | 20 | dlfzfutozd(omgolpsgyi) = 0% vs 15% vs 0% phesggmlbk (wrrgkflrai ) View more | Positive | 21 Oct 2018 | |||
Phase 2 | 185 | cnjyqmvflw(bzjedvzuhg) = wcwceuwabm sshiluahvb (etvzvvcebg ) View more | Negative | 01 Aug 2016 | |||
Placebo | cnjyqmvflw(bzjedvzuhg) = fvmnlkauzg sshiluahvb (etvzvvcebg ) View more | ||||||
Phase 2 | 185 | exkooxgune(wxpptmdbhb) = qqxrsxgrjl etiompkzow (eohgzimzgw ) View more | - | 20 May 2014 | |||
Placebo | exkooxgune(wxpptmdbhb) = kuejxfgcoi etiompkzow (eohgzimzgw ) View more |